Keith J. Lane - 17 Sep 2026 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Reporting relationship: EVP, Clinical and Regulatory
Issuer ticker: KPRX
Reported as of: 17 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Sep 2026, 21:35:25 UTC
Prior SEC filing: 17 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Melissa Tosca, Attorney-in-Fact

Filing notes and source

Key filing fact

Keith J. Lane filed Form 4 for KIORA PHARMACEUTICALS INC (KPRX) on 17 Sep 2026.

Key facts

This page summarizes Keith J. Lane's Form 4 filing for KIORA PHARMACEUTICALS INC (KPRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Sep 2026, 21:35.

Change

Previous filing in this sequence was filed on 17 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002155788 Primary reporting owner

Lane Keith J.

Relationship: EVP, Clinical and Regulatory
Address: 169 SAXONY RD., SUITE 212, ENCINITAS
Signature: /s/ Melissa Tosca, Attorney-in-Fact
Signature date: 17 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KPRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +55,000
Change %
Price: $0.000000^*
Shares after: 55,000
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,000
Exercise price: $2.67
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on September 17, 2027, and the remaining balance vests monthly on the last day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.